+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Specialty Generics Market - Global Forecast to 2030- Product Image
Specialty Generics Market - Global Forecast to 2030- Product Image
Sale

Specialty Generics Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 183 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6012051
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Specialty Generics Market grew from USD 93.56 billion in 2024 to USD 103.78 billion in 2025. It is expected to continue growing at a CAGR of 10.83%, reaching USD 173.44 billion by 2030.

The specialty generics sector is undergoing a critical phase characterized by intense innovation, heightened regulatory scrutiny, and evolving market dynamics. As healthcare systems worldwide strive to balance cost containment with patient access to advanced therapies, specialty generics have emerged as a strategic bridge. These products, designed to mirror the safety and efficacy of their branded counterparts, help reduce healthcare expenditure while ensuring continuity of care for chronic and complex conditions.

This executive summary provides a holistic view of recent developments influencing the specialty generics landscape. It underscores key transformations, analyzes the impact of newly imposed tariffs, and offers granular insights drawn from multiple market segmentation dimensions. In addition, it highlights geographical nuances, profiles leading industry participants, and presents actionable strategic recommendations for decision-makers. By synthesizing these insights, stakeholders will gain a clear understanding of emerging opportunities, potential risks, and optimal pathways to strengthen their market positioning and foster sustainable growth.

Transformative Shifts in the Specialty Generics Landscape

Over the past several years, three major trends have fundamentally reshaped the specialty generics arena. First, the integration of advanced formulation technologies-ranging from lyophilized powders in injectable dosage forms to extended-release tablets in oral therapies-has enhanced product differentiation and patient adherence. Second, regulatory pathways have been streamlined through harmonized bioequivalence requirements and accelerated approval frameworks, reducing time-to-market for complex generics.

Third, digital transformation is revolutionizing end-to-end processes. Manufacturers are deploying data-driven predictive modeling to optimize capsule and tablet formulation, while contract development organizations adopt recombinant DNA technology for biologics and biosimilars. Meanwhile, supply chain players embrace blockchain and IoT solutions to fortify traceability from active pharmaceutical ingredient sourcing to final dosage unit distribution. Collectively, these shifts are fostering a more agile, transparent, and resilient specialty generics ecosystem, enabling stakeholders to respond swiftly to evolving patient needs and regulatory expectations.

Cumulative Impact of United States Tariffs 2025

In 2025, the United States enacted a series of targeted tariffs affecting both finished specialty generics and key intermediates. Raw materials for beta-lactam antibiotics, lipid-lowering agents, and certain antihypertensive APIs saw duty increases of up to 10%. These measures have led to upward pressure on production costs, particularly for manufacturers relying on overseas small molecule sourcing. Concurrently, tariff adjustments on monoclonal antibody production reagents have increased expenditure for biosimilars, prompting some firms to relocate recombinant DNA technology facilities closer to API suppliers to maintain cost discipline.

Despite these headwinds, many companies are leveraging economies of scale in vial-based injections and pre-filled syringes to offset additional duties. They are also diversifying supply chains by establishing partnerships in low-cost manufacturing hubs. While the cumulative tariff impact has introduced short-term margin compression, it is accelerating strategic realignment towards vertical integration, local API production, and selective in-licensing of complex generics to preserve long-term competitiveness.

Key Segmentation Insights Driving Market Dynamics

A multi-dimensional segmentation approach reveals nuanced growth drivers across product, drug class, end-user, application, manufacturing process, route of administration, patient demographics, and purchasing patterns. Within inhalation dosage forms, the adoption of dry powder inhalers is rising due to improved stability and patient convenience, while nebulizers continue to serve critical care settings. Injectable dosage forms, including lyophilized powders, pre-filled syringes, and vials, dominate high-value biosimilars and oncology portfolios. In the oral segment, extended-release and immediate-release tablets account for the bulk of prescriptions, while chewable and effervescent formats cater to niche pediatric and geriatric subgroups. Topical creams, gels, ointments, and patches are increasingly leveraged for pain management and dermatological conditions.

On the drug class front, non-opioid analgesics remain the backbone of pain therapy, even as opioid alternatives draw regulatory attention. Beta-lactams and cephalosporins lead antibiotics usage, while macrolides gain traction in respiratory indications. Selective serotonin reuptake inhibitors outpace serotonin-norepinephrine inhibitors in the antidepressant market, and insulin sensitizers complement DPP-4 inhibitors in antidiabetic regimens. Hospitals, public and private, continue to drive demand for high-complexity generics, whereas online and retail pharmacies offer rapid dispensing for chronic care medications. Manufacturing excellence spans both biologics with monoclonal antibody platforms and small molecule techniques in capsule and tablet formulation. Intravenous, oral, and subcutaneous routes serve diverse therapeutic needs, and demographic-specific formulations address geriatric and pediatric patient safety. Finally, bulk purchasing agreements with large health systems contrast with individual consumer demand via retail channels, underscoring the importance of flexible commercial models.

Key Regional Insights Shaping Growth Trajectories

Geographical analysis highlights distinct opportunity zones and competitive pressures. In the Americas, strong generic substitution policies and robust healthcare spending underpin rapid uptake of injectable and topical generics, particularly for oncology and pain management applications. Latin American markets are emerging as cost-effective manufacturing bases, while North America remains the largest consumer market.

In Europe, Middle East & Africa, rigorous pricing controls and tender-based procurement shape competitive dynamics. Western Europe excels in biologics/biosimilars innovation, and the Middle East is advancing local pharmaceutical capacity. Africa presents growth potential through expanding hospital networks and rising demand for affordable analgesic and antibiotic generics.

Asia-Pacific continues to serve as both manufacturing powerhouse and growing end-use market. India and China dominate small molecule production, whereas Southeast Asia is attracting investments in lyophilization and recombinant DNA technology. Patient demographics and expanding health insurance coverage in emerging APAC economies are driving higher per capita consumption of specialty generics across cardiovascular, oncology, and diabetes care.

Key Company Insights Spotlighting Major Players

Leading global players demonstrate diverse strategic postures in specialty generics. Akorn Operating Company LLC prioritizes injectable biosimilars, while Apotex Inc. leverages strong oral dosage form capabilities. Aspen Group has invested heavily in high-potency formulations, and Aurobindo Pharma Limited focuses on integrated small molecule production. Bausch Health Companies Inc. blends niche topical therapies with cardiovascular agents, and Cipla Limited is expanding its respiratory inhalation franchise.

Dr. Reddy’s Laboratories Ltd. and Fresenius Kabi AG drive innovation in recombinant DNA and sterile injectable processes, respectively. Endo International plc and Generic Specialties, Inc. excel in analgesics, whereas Hikma Pharmaceuticals PLC has carved out a leadership position in pre-filled syringes. Lupin Limited and Mallinckrodt Pharmaceuticals emphasize extended-release and lyophilized powders. Novartis AG and Pfizer Inc. continue to defend biosimilar portfolios, and STADA Arzneimittel AG maintains a strong presence in European tender markets. Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., and Zydus Group round out the competitive landscape with extensive generics pipelines, from antibiotics to antidepressants.

Actionable Recommendations for Industry Leadership

To thrive in this evolving environment, industry leaders should pursue five core actions. First, invest in localized API production and strategic partnerships to mitigate tariff exposure and secure supply continuity. Second, accelerate R&D in advanced formulation technologies, including lyophilization, extended-release matrices, and recombinant DNA platforms, to differentiate pipelines. Third, refine commercial models by balancing bulk contracts with health systems against direct-to-consumer channels and digital pharmacies.

Fourth, adopt end-to-end digital solutions-spanning predictive analytics for manufacturing quality to blockchain-enabled traceability in logistics-to enhance operational resilience. Fifth, strengthen portfolio diversification across therapeutic areas, integrating high-growth segments such as oncology, cardiovascular diseases, and pain management with established analgesic, antibiotic, and antidepressant offerings. By executing these priorities, companies will enhance agility, unlock new revenue streams, and reinforce their leadership positions in specialty generics.

Conclusion: Navigating the Specialty Generics Frontier

The specialty generics market stands at a pivotal juncture driven by technological innovation, regulatory evolution, and shifting trade policies. Stakeholders who embrace advanced formulation methods, fortify supply chains, and leverage data-driven operations will secure a competitive edge. Concurrently, a nuanced understanding of segmentation dynamics and regional nuances will enable more informed investment and commercial decisions.

As tariffs introduce new cost considerations, proactive supply chain realignment and local manufacturing investments will be critical. Meanwhile, collaboration between generics manufacturers, contract development organizations, and logistical partners can accelerate time-to-market and expand global reach. By integrating these insights into strategic planning, organizations can capture emerging opportunities and deliver high-value therapies to patients worldwide.

Market Segmentation & Coverage

This research report categorizes the Specialty Generics Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Inhalation Dosage Forms
    • Dry Powder Inhalers
    • Nebulizers
  • Injectable Dosage Forms
    • Lyophilized Powders
    • Pre-Filled Syringes
    • Vial-Based Injections
  • Oral Dosage Forms
    • Chewable Tablets
    • Effervescent Tablets
    • Extended-Release Tablets
    • Immediate Release Tablets
  • Topical Dosage Forms
    • Creams
    • Gels
    • Ointments
    • Patches
  • Analgesics
    • Non-Opioid Analgesics
    • Opioid Analgesics
  • Antibiotics
    • Beta-Lactams
    • Cephalosporins
    • Macrolides
  • Antidepressants
    • Selective Serotonin Reuptake Inhibitors
    • Serotonin-Norepinephrine Reuptake Inhibitors
  • Antidiabetics
    • Dipeptidyl Peptidase-4 Inhibitors
    • Insulin Sensitizers
  • Hospitals
    • Public Hospitals
  • Online Pharmacies
  • Retails Pharmacies
    • Chain Pharmacies
    • Independent Pharmacies
  • Cardiovascular Diseases
    • Antihypertensive Agents
    • Lipid-Lowering Agents
  • Oncology
    • Chemotherapy Agents
    • Targeted Therapy Agents
  • Pain Management
    • Analgesic Medications
    • Nerve Blockers
  • Biologics/Biosimilars
    • Monoclonal Antibody Production
    • Recombinant DNA Technology
  • Small Molecule Generics
    • Capsule Formulation Techniques
    • Tablet Formulation Techniques
  • Intravenous
  • Oral
  • Subcutaneous
  • Geriatric
  • Pediatric
  • Bulk Purchasers
  • Individual Consumers

This research report categorizes the Specialty Generics Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Specialty Generics Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Akorn Operating Company LLC
  • Apotex Inc.
  • Aspen Group
  • Aurobindo Pharma Limited
  • Bausch Health Companies Inc.
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Endo International plc
  • Fresenius Kabi AG
  • Generic Specialties, Inc.
  • Hikma Pharmaceuticals PLC
  • Lupin Limited
  • Mallinckrodt Pharmaceuticals
  • Novartis AG
  • Pfizer Inc.
  • STADA Arzneimittel AG
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Zydus Group

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Specialty Generics Market, by Product Type
8.1. Introduction
8.2. Inhalation Dosage Forms
8.2.1. Dry Powder Inhalers
8.2.2. Nebulizers
8.3. Injectable Dosage Forms
8.3.1. Lyophilized Powders
8.3.2. Pre-Filled Syringes
8.3.3. Vial-Based Injections
8.4. Oral Dosage Forms
8.4.1. Chewable Tablets
8.4.2. Effervescent Tablets
8.4.3. Extended-Release Tablets
8.4.4. Immediate Release Tablets
8.5. Topical Dosage Forms
8.5.1. Creams
8.5.2. Gels
8.5.3. Ointments
8.5.4. Patches
9. Specialty Generics Market, by Drug Class
9.1. Introduction
9.2. Analgesics
9.2.1. Non-Opioid Analgesics
9.2.2. Opioid Analgesics
9.3. Antibiotics
9.3.1. Beta-Lactams
9.3.2. Cephalosporins
9.3.3. Macrolides
9.4. Antidepressants
9.4.1. Selective Serotonin Reuptake Inhibitors
9.4.2. Serotonin-Norepinephrine Reuptake Inhibitors
9.5. Antidiabetics
9.5.1. Dipeptidyl Peptidase-4 Inhibitors
9.5.2. Insulin Sensitizers
10. Specialty Generics Market, by End-User
10.1. Introduction
10.2. Hospitals
10.2.1. Public Hospitals
10.3. Online Pharmacies
10.4. Retails Pharmacies
10.4.1. Chain Pharmacies
10.4.2. Independent Pharmacies
11. Specialty Generics Market, by Application
11.1. Introduction
11.2. Cardiovascular Diseases
11.2.1. Antihypertensive Agents
11.2.2. Lipid-Lowering Agents
11.3. Oncology
11.3.1. Chemotherapy Agents
11.3.2. Targeted Therapy Agents
11.4. Pain Management
11.4.1. Analgesic Medications
11.4.2. Nerve Blockers
12. Specialty Generics Market, by Manufacturing Process
12.1. Introduction
12.2. Biologics/Biosimilars
12.2.1. Monoclonal Antibody Production
12.2.2. Recombinant DNA Technology
12.3. Small Molecule Generics
12.3.1. Capsule Formulation Techniques
12.3.2. Tablet Formulation Techniques
13. Specialty Generics Market, by Route of Administration
13.1. Introduction
13.2. Intravenous
13.3. Oral
13.4. Subcutaneous
14. Specialty Generics Market, by Patient Demographics
14.1. Introduction
14.2. Geriatric
14.3. Pediatric
15. Specialty Generics Market, by Purchasing Patterns
15.1. Introduction
15.2. Bulk Purchasers
15.3. Individual Consumers
16. Americas Specialty Generics Market
16.1. Introduction
16.2. Argentina
16.3. Brazil
16.4. Canada
16.5. Mexico
16.6. United States
17. Asia-Pacific Specialty Generics Market
17.1. Introduction
17.2. Australia
17.3. China
17.4. India
17.5. Indonesia
17.6. Japan
17.7. Malaysia
17.8. Philippines
17.9. Singapore
17.10. South Korea
17.11. Taiwan
17.12. Thailand
17.13. Vietnam
18. Europe, Middle East & Africa Specialty Generics Market
18.1. Introduction
18.2. Denmark
18.3. Egypt
18.4. Finland
18.5. France
18.6. Germany
18.7. Israel
18.8. Italy
18.9. Netherlands
18.10. Nigeria
18.11. Norway
18.12. Poland
18.13. Qatar
18.14. Russia
18.15. Saudi Arabia
18.16. South Africa
18.17. Spain
18.18. Sweden
18.19. Switzerland
18.20. Turkey
18.21. United Arab Emirates
18.22. United Kingdom
19. Competitive Landscape
19.1. Market Share Analysis, 2024
19.2. FPNV Positioning Matrix, 2024
19.3. Competitive Analysis
19.3.1. Akorn Operating Company LLC
19.3.2. Apotex Inc.
19.3.3. Aspen Group
19.3.4. Aurobindo Pharma Limited
19.3.5. Bausch Health Companies Inc.
19.3.6. Cipla Limited
19.3.7. Dr. Reddy's Laboratories Ltd.
19.3.8. Endo International plc
19.3.9. Fresenius Kabi AG
19.3.10. Generic Specialties, Inc.
19.3.11. Hikma Pharmaceuticals PLC
19.3.12. Lupin Limited
19.3.13. Mallinckrodt Pharmaceuticals
19.3.14. Novartis AG
19.3.15. Pfizer Inc.
19.3.16. STADA Arzneimittel AG
19.3.17. Sun Pharmaceutical Industries Ltd.
19.3.18. Teva Pharmaceutical Industries Ltd.
19.3.19. Viatris Inc.
19.3.20. Zydus Group
20. ResearchAI
21. ResearchStatistics
22. ResearchContacts
23. ResearchArticles
24. Appendix
List of Figures
FIGURE 1. SPECIALTY GENERICS MARKET MULTI-CURRENCY
FIGURE 2. SPECIALTY GENERICS MARKET MULTI-LANGUAGE
FIGURE 3. SPECIALTY GENERICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL SPECIALTY GENERICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY MANUFACTURING PROCESS, 2024 VS 2030 (%)
FIGURE 16. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY MANUFACTURING PROCESS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 18. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2030 (%)
FIGURE 20. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY PURCHASING PATTERNS, 2024 VS 2030 (%)
FIGURE 22. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY PURCHASING PATTERNS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 26. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. EUROPE, MIDDLE EAST & AFRICA SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 30. EUROPE, MIDDLE EAST & AFRICA SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. SPECIALTY GENERICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 32. SPECIALTY GENERICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. SPECIALTY GENERICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL SPECIALTY GENERICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY INHALATION DOSAGE FORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY DRY POWDER INHALERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY NEBULIZERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY INHALATION DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY INJECTABLE DOSAGE FORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY LYOPHILIZED POWDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY PRE-FILLED SYRINGES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY VIAL-BASED INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY INJECTABLE DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY ORAL DOSAGE FORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY CHEWABLE TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY EFFERVESCENT TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY EXTENDED-RELEASE TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY IMMEDIATE RELEASE TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY ORAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY TOPICAL DOSAGE FORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY CREAMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY GELS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY PATCHES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY TOPICAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY ANALGESICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY NON-OPIOID ANALGESICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY OPIOID ANALGESICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY BETA-LACTAMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY ANTIDIABETICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY DIPEPTIDYL PEPTIDASE-4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY INSULIN SENSITIZERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY ANTIDIABETICS, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY RETAILS PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY RETAILS PHARMACIES, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY ANTIHYPERTENSIVE AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY LIPID-LOWERING AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY TARGETED THERAPY AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY ANALGESIC MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY NERVE BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY BIOLOGICS/BIOSIMILARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY MONOCLONAL ANTIBODY PRODUCTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY BIOLOGICS/BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE GENERICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY CAPSULE FORMULATION TECHNIQUES, BY REGION, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY TABLET FORMULATION TECHNIQUES, BY REGION, 2018-2030 (USD MILLION)
TABLE 76. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE GENERICS, 2018-2030 (USD MILLION)
TABLE 77. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 78. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 79. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 80. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 81. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 82. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 83. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 84. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY PURCHASING PATTERNS, 2018-2030 (USD MILLION)
TABLE 85. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY BULK PURCHASERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 86. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY INDIVIDUAL CONSUMERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY INHALATION DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY INJECTABLE DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY ORAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 91. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY TOPICAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 92. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 93. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 94. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 95. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
TABLE 96. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY ANTIDIABETICS, 2018-2030 (USD MILLION)
TABLE 97. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 98. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 99. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY RETAILS PHARMACIES, 2018-2030 (USD MILLION)
TABLE 100. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 101. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 102. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 103. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 104. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 105. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY BIOLOGICS/BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 106. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE GENERICS, 2018-2030 (USD MILLION)
TABLE 107. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 108. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 109. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY PURCHASING PATTERNS, 2018-2030 (USD MILLION)
TABLE 110. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA SPECIALTY GENERICS MARKET SIZE, BY INHALATION DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA SPECIALTY GENERICS MARKET SIZE, BY INJECTABLE DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA SPECIALTY GENERICS MARKET SIZE, BY ORAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA SPECIALTY GENERICS MARKET SIZE, BY TOPICAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 116. ARGENTINA SPECIALTY GENERICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 117. ARGENTINA SPECIALTY GENERICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 118. ARGENTINA SPECIALTY GENERICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA SPECIALTY GENERICS MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
TABLE 120. ARGENTINA SPECIALTY GENERICS MARKET SIZE, BY ANTIDIABETICS, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA SPECIALTY GENERICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA SPECIALTY GENERICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 123. ARGENTINA SPECIALTY GENERICS MARKET SIZE, BY RETAILS PHARMACIES, 2018-2030 (USD MILLION)
TABLE 124. ARGENTINA SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 125. ARGENTINA SPECIALTY GENERICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 126. ARGENTINA SPECIALTY GENERICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 127. ARGENTINA SPECIALTY GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 128. ARGENTINA SPECIALTY GENERICS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 129. ARGENTINA SPECIALTY GENERICS MARKET SIZE, BY BIOLOGICS/BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE GENERICS, 2018-2030 (USD MILLION)
TABLE 131. ARGENTINA SPECIALTY GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 132. ARGENTINA SPECIALTY GENERICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 133. ARGENTINA SPECIALTY GENERICS MARKET SIZE, BY PURCHASING PATTERNS, 2018-2030 (USD MILLION)
TABLE 134. BRAZIL SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 135. BRAZIL SPECIALTY GENERICS MARKET SIZE, BY INHALATION DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 136. BRAZIL SPECIALTY GENERICS MARKET SIZE, BY INJECTABLE DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 137. BRAZIL SPECIALTY GENERICS MARKET SIZE, BY ORAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 138. BRAZIL SPECIALTY GENERICS MARKET SIZE, BY TOPICAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 139. BRAZIL SPECIALTY GENERICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 140. BRAZIL SPECIALTY GENERICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 141. BRAZIL SPECIALTY GENERICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 142. BRAZIL SPECIALTY GENERICS MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
TABLE 143. BRAZIL SPECIALTY GENERICS MARKET SIZE, BY ANTIDIABETICS, 2018-2030 (USD MILLION)
TABLE 144. BRAZIL SPECIALTY GENERICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 145. BRAZIL SPECIALTY GENERICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 146. BRAZIL SPECIALTY GENERICS MARKET SIZE, BY RETAILS PHARMACIES, 2018-2030 (USD MILLION)
TABLE 147. BRAZIL SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 148. BRAZIL SPECIALTY GENERICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 149. BRAZIL SPECIALTY GENERICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 150. BRAZIL SPECIALTY GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 151. BRAZIL SPECIALTY GENERICS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 152. BRAZIL SPECIALTY GENERICS MARKET SIZE, BY BIOLOGICS/BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 153. BRAZIL SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE GENERICS, 2018-2030 (USD MILLION)
TABLE 154. BRAZIL SPECIALTY GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 155. BRAZIL SPECIALTY GENERICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 156. BRAZIL SPECIALTY GENERICS MARKET SIZE, BY PURCHASING PATTERNS, 2018-2030 (USD MILLION)
TABLE 157. CANADA SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 158. CANADA SPECIALTY GENERICS MARKET SIZE, BY INHALATION DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 159. CANADA SPECIALTY GENERICS MARKET SIZE, BY INJECTABLE DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 160. CANADA SPECIALTY GENERICS MARKET SIZE, BY ORAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 161. CANADA SPECIALTY GENERICS MARKET SIZE, BY TOPICAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 162. CANADA SPECIALTY GENERICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 163. CANADA SPECIALTY GENERICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 164. CANADA SPECIALTY GENERICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 165. CANADA SPECIALTY GENERICS MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
TABLE 166. CANADA SPECIALTY GENERICS MARKET SIZE, BY ANTIDIABETICS, 2018-2030 (USD MILLION)
TABLE 167. CANADA SPECIALTY GENERICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 168. CANADA SPECIALTY GENERICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 169. CANADA SPECIALTY GENERICS MARKET SIZE, BY RETAILS PHARMACIES, 2018-2030 (USD MILLION)
TABLE 170. CANADA SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 171. CANADA SPECIALTY GENERICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 172. CANADA SPECIALTY GENERICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 173. CANADA SPECIALTY GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 174. CANADA SPECIALTY GENERICS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 175. CANADA SPECIALTY GENERICS MARKET SIZE, BY BIOLOGICS/BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 176. CANADA SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE GENERICS, 2018-2030 (USD MILLION)
TABLE 177. CANADA SPECIALTY GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 178. CANADA SPECIALTY GENERICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 179. CANADA SPECIALTY GENERICS MARKET SIZE, BY PURCHASING PATTERNS, 2018-2030 (USD MILLION)
TABLE 180. MEXICO SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 181. MEXICO SPECIALTY GENERICS MARKET SIZE, BY INHALATION DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 182. MEXICO SPECIALTY GENERICS MARKET SIZE, BY INJECTABLE DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 183. MEXICO SPECIALTY GENERICS MARKET SIZE, BY ORAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 184. MEXICO SPECIALTY GENERICS MARKET SIZE, BY TOPICAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 185. MEXICO SPECIALTY GENERICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 186. MEXICO SPECIALTY GENERICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 187. MEXICO SPECIALTY GENERICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 188. MEXICO SPECIALTY GENERICS MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
TABLE 189. MEXICO SPECIALTY GENERICS MARKET SIZE, BY ANTIDIABETICS, 2018-2030 (USD MILLION)
TABLE 190. MEXICO SPECIALTY GENERICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 191. MEXICO SPECIALTY GENERICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 192. MEXICO SPECIALTY GENERICS MARKET SIZE, BY RETAILS PHARMACIES, 2018-2030 (USD MILLION)
TABLE 193. MEXICO SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 194. MEXICO SPECIALTY GENERICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 195. MEXICO SPECIALTY GENERICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 196. MEXICO SPECIALTY GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 197. MEXICO SPECIALTY GENERICS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 198. MEXICO SPECIALTY GENERICS MARKET SIZE, BY BIOLOGICS/BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 199. MEXICO SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE GENERICS, 2018-2030 (USD MILLION)
TABLE 200. MEXICO SPECIALTY GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 201. MEXICO SPECIALTY GENERICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 202. MEXICO SPECIALTY GENERICS MARKET SIZE, BY PURCHASING PATTERNS, 2018-2030 (USD MILLION)
TABLE 203. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 204. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY INHALATION DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 205. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY INJECTABLE DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 206. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY ORAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 207. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY TOPICAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 208. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 209. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 210. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 211. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
TABLE 212. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY ANTIDIABETICS, 2018-2030 (USD MILLION)
TABLE 213. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 214. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 215. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY RETAILS PHARMACIES, 2018-2030 (USD MILLION)
TABLE 216. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 217. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 218. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 219. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 220. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 221. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY BIOLOGICS/BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 222. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE GENERICS, 2018-2030 (USD MILLION)
TABLE 223. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 224. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 225. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY PURCHASING PATTERNS, 2018-2030 (USD MILLION)
TABLE 226. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 227. ASIA-PACIFIC SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 228. ASIA-PACIFIC SPECIALTY GENERICS MARKET SIZE, BY INHALATION DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 229. ASIA-PACIFIC SPECIALTY GENERICS MARKET SIZE, BY INJECTABLE DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 230. ASIA-PACIFIC SPECIALTY GENERICS MARKET SIZE, BY ORAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 231. ASIA-PACIFIC SPECIALTY GENERICS MARKET SIZE, BY TOPICAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 232. ASIA-PACIFIC SPECIALTY GENERICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 233. ASIA-PACIFIC SPECIALTY GENERICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 234. ASIA-PACIFIC SPECIALTY GENERICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 235. ASIA-PACIFIC SPECIALTY GENERICS MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
TABLE 236. ASIA-PACIFIC SPECIALTY GENERICS MARKET SIZE, BY ANTIDIABETICS, 2018-2030 (USD MILLION)
TABLE 237. ASIA-PACIFIC SPECIALTY GENERICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 238. ASIA-PACIFIC SPECIALTY GENERICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 239. ASIA-PACIFIC SPECIALTY GENERICS MARKET SIZE, BY RETAILS PHARMACIES, 2018-2030 (USD MILLION)
TABLE 240. ASIA-PACIFIC SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 241. ASIA-PACIFIC SPECIALTY GENERICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 242. ASIA-PACIFIC SPECIALTY GENERICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 243. ASIA-PACIFIC SPECIALTY GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 244. ASIA-PACIFIC SPECIALTY GENERICS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 245. ASIA-PACIFIC SPECIALTY GENERICS MARKET SIZE, BY BIOLOGICS/BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 246. ASIA-PACIFIC SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE GENERICS, 2018-2030 (USD MILLION)
TABLE 247. ASIA-PACIFIC SPECIALTY GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 248. ASIA-PACIFIC SPECIALTY GENERICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 249. ASIA-PACIFIC SPECIALTY GENERICS MARKET SIZE, BY PURCHASING PATTERNS, 2018-2030 (USD MILLION)
TABLE 250. ASIA-PACIFIC SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 251. AUSTRALIA SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 252. AUSTRALIA SPECIALTY GENERICS MARKET SIZE, BY INHALATION DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 253. AUSTRALIA SPECIALTY GENERICS MARKET SIZE, BY INJECTABLE DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 254. AUSTRALIA SPECIALTY GENERICS MARKET SIZE, BY ORAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 255. AUSTRALIA SPECIALTY GENERICS MARKET SIZE, BY TOPICAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 256. AUSTRALIA SPECIALTY GENERICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 257. AUSTRALIA SPECIALTY GENERICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 258. AUSTRALIA SPECIALTY GENERICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 259. AUSTRALIA SPECIALTY GENERICS MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
TABLE 260. AUSTRALIA SPECIALTY GENERICS MARKET SIZE, BY ANTIDIABETICS, 2018-2030 (USD MILLION)
TABLE 261. AUSTRALIA SPECIALTY GENERICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 262. AUSTRALIA SPECIALTY GENERICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 263. AUSTRALIA SPECIALTY GENERICS MARKET SIZE, BY RETAILS PHARMACIES, 2018-2030 (USD MILLION)
TABLE 264. AUSTRALIA SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 265. AUSTRALIA SPECIALTY GENERICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 266. AUSTRALIA SPECIALTY GENERICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 267. AUSTRALIA SPECIALTY GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 268. AUSTRALIA SPECIALTY GENERICS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 269. AUSTRALIA SPECIALTY GENERICS MARKET SIZE, BY BIOLOGICS/BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 270. AUSTRALIA SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE GENERICS, 2018-2030 (USD MILLION)
TABLE 271. AUSTRALIA SPECIALTY GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 272. AUSTRALIA SPECIALTY GENERICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 273. AUSTRALIA SPECIALTY GENERICS MARKET SIZE, BY PURCHASING PATTERNS, 2018-2030 (USD MILLION)
TABLE 274. CHINA SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 275. CHINA SPECIALTY GENERICS MARKET SIZE, BY INHALATION DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 276. CHINA SPECIALTY GENERICS MARKET SIZE, BY INJECTABLE DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 277. CHINA SPECIALTY GENERICS MARKET SIZE, BY ORAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 278. CHINA SPECIALTY GENERICS MARKET SIZE, BY TOPICAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 279. CHINA SPECIALTY GENERICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 280. CHINA SPECIALTY GENERICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 281. CHINA SPECIALTY GENERICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 282. CHINA SPECIALTY GENERICS MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
TABLE 283. CHINA SPECIALTY GENERICS MARKET SIZE, BY ANTIDIABETICS, 2018-2030 (USD MILLION)
TABLE 284. CHINA SPECIALTY GENERICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 285. CHINA SPECIALTY GENERICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 286. CHINA SPECIALTY GENERICS MARKET SIZE, BY RETAILS PHARMACIES, 2018-2030 (USD MILLION)
TABLE 287. CHINA SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 288. CHINA SPECIALTY GENERICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 289. CHINA SPECIALTY GENERICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 290. CHINA SPECIALTY GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 291. CHINA SPECIALTY GENERICS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 292. CHINA SPECIALTY GENERICS MARKET SIZE, BY BIOLOGICS/BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 293. CHINA SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE GENERICS, 2018-2030 (USD MILLION)
TABLE 294. CHINA SPECIALTY GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 295. CHINA SPECIALTY GENERICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 296. CHINA SPECIALTY GENERICS MARKET SIZE, BY PURCHASING PATTERNS, 2018-2030 (USD MILLION)
TABLE 297. INDIA SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 298. INDIA SPECIALTY GENERICS MARKET SIZE, BY INHALATION DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 299. INDIA SPECIALTY GENERICS MARKET SIZE, BY INJECTABLE DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 300. INDIA SPECIALTY GENERICS MARKET SIZE, BY ORAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 301. INDIA SPECIALTY GENERICS MARKET SIZE, BY TOPICAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 302. INDIA SPECIALTY GENERICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 303. INDIA SPECIALTY GENERICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 304. INDIA SPECIALTY GENERICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 305. INDIA SPECIALTY GENERICS MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
TABLE 306. INDIA SPECIALTY GENERICS MARKET SIZE, BY ANTIDIABETICS, 2018-2030 (USD MILLION)
TABLE 307. INDIA SPECIALTY GENERICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 308. INDIA SPECIALTY GENERICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 309. INDIA SPECIALTY GENERICS MARKET SIZE, BY RETAILS PHARMACIES, 2018-2030 (USD MILLION)
TABLE 310. INDIA SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 311. INDIA SPECIALTY GENERICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 312. INDIA SPECIALTY GENERICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 313. INDIA SPECIALTY GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 314. INDIA SPECIALTY GENERICS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 315. INDIA SPECIALTY GENERICS MARKET SIZE, BY BIOLOGICS/BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 316. INDIA SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE GENERICS, 2018-2030 (USD MILLION)
TABLE 317. INDIA SPECIALTY GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 318. INDIA SPECIALTY GENERICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 319. INDIA SPECIALTY GENERICS MARKET SIZE, BY PURCHASING PATTERNS, 2018-2030 (USD MILLION)
TABLE 320. INDONESIA SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 321. INDONESIA SPECIALTY GENERICS MARKET SIZE, BY INHALATION DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 322. INDONESIA SPECIALTY GENERICS MARKET SIZE, BY INJECTABLE DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 323. INDONESIA SPECIALTY GENERICS MARKET SIZE, BY ORAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 324. INDONESIA SPECIALTY GENERICS MARKET SIZE, BY TOPICAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 325. INDONESIA SPECIALTY GENERICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 326. INDONESIA SPECIALTY GENERICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
TABLE 327. INDONESIA SPECIALTY GENERICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 328. INDONESIA SPECIALTY GENERICS MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2030 (USD MILLION)
TABLE 329. INDONESIA SPECIALTY GENERICS MARKET SIZE, BY ANTIDIABETICS, 2018-2030 (USD MILLION)
TABLE 330. INDONESIA SPECIALTY GENERICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 331. INDONESIA SPECIALTY GENERICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 332. INDONESIA SPECIALTY GENERICS MARKET SIZE, BY RETAILS PHARMACIES, 2018-2030 (USD MILLION)
TABLE 333. INDONESIA SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 334. INDONESIA SPECIALTY GENERICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILL

Companies Mentioned

  • Akorn Operating Company LLC
  • Apotex Inc.
  • Aspen Group
  • Aurobindo Pharma Limited
  • Bausch Health Companies Inc.
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Endo International plc
  • Fresenius Kabi AG
  • Generic Specialties, Inc.
  • Hikma Pharmaceuticals PLC
  • Lupin Limited
  • Mallinckrodt Pharmaceuticals
  • Novartis AG
  • Pfizer Inc.
  • STADA Arzneimittel AG
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Zydus Group

Methodology

Loading
LOADING...

Related Topics

Related Reports

Hedgehog Pathway Inhibitors Market by Generic Drug Name, Dosage, Distribution Channel, Cancer Indication, End-Users - Global Forecast 2025-2030 - Product Image

Hedgehog Pathway Inhibitors Market by Generic Drug Name, Dosage, Distribution Channel, Cancer Indication, End-Users - Global Forecast 2025-2030

  • Report
  • 188 Pages
  • Global
From
Speciality Generics Market Report and Forecast 2024-2032 - Product Image

Speciality Generics Market Report and Forecast 2024-2032

  • Report
  • 200 Pages
  • Global
From
Specialty Generics Market Report 2025-2033 - Product Image

Specialty Generics Market Report 2025-2033

  • Report
  • 127 Pages
  • Global
From
Specialty Generics - Global Strategic Business Report - Product Image

Specialty Generics - Global Strategic Business Report

  • Report
  • 94 Pages
  • Global
From
Branded Generics Market - Global Forecast to 2030 - Product Image

Branded Generics Market - Global Forecast to 2030

  • Report
  • 185 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.